Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Disease Progression to 3st Generation Epidermal Growth Factor Receptor-tyrosine Kinase InhibitorEGFR-TKI Osimertinib
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Aspirin (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Nov 2019 Planned number of patients changed from 200 to 100.
- 29 Nov 2019 Planned End Date changed from 30 Jun 2022 to 31 Dec 2022.
- 29 Nov 2019 Planned primary completion date changed from 30 Jun 2019 to 31 Dec 2021.